August 29, 2012
The pig production industry in Estonia, Latvia, and Lithuania
has gained access to Uniferon®, the industry-leading injectable
iron supplement.
A recent introduction of the industry-leading injectable iron
supplement Uniferon® to pig producers in the Baltics is yet another
step into the world for the Danish pharmaceutical company
Pharmacosmos. And a stepping stone for the Baltic pig farmers' work
towards being more competitive.
Pharmacosmos is acknowledged as a global leader in iron deficiency
treatments for both humans and animals, and the company's Uniferon,
which is an all-natural injectable iron supplement for newborn
piglets, is used by pig farmers throughout the world.
"Pig production in the Baltics is becoming increasingly focused on
global best practice and hence also the generally accepted standard
of administering iron to newborn piglets to promote optimal growth
and general health as well as avoiding detrimental anaemia. Pig
producers in the Baltics are thus becoming increasingly demanding
and we are glad that we are now able to support their efforts,"
said Jens Fabricius, Vice President, Marketing & Business
Operations at Pharmacosmos.
Uniferon is marketed through Magnum Veterinarija, a dedicated,
long-standing veterinarian-focused partner based in Estonia with
subsidiaries in Latvia and Lithuania.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.